Shilpa Medicare's Subsidiary Partners with mAbTree Biologics for a Breakthrough Cancer Drug

Shilpa Biologicals, a wholly-owned subsidiary of

, has entered a strategic partnership with Switzerland-based mAbTree Biologics AG to co-develop and commercialize a novel biological entity (NBE) for immuno-oncology. Under the agreement, Shilpa Biologicals will support the development of mAbTree’s checkpoint inhibitor, conduct first-in-human clinical trials, and provide long-term commercial supply through its GMP-certified manufacturing facility in Dharwad, Karnataka. The drug, targeting a novel immune checkpoint protein, aims to enhance T-cell activation, making resistant tumors more responsive to treatment, including lung cancer, head and neck squamous cell carcinoma, and hematologic malignancies. This breakthrough approach could convert "cold" tumors with low immune response into "hot" tumors with better immune infiltration, potentially improving chemotherapy outcomes. The collaboration strengthens Shilpa Biologicals' position in innovative oncology therapeutics, leveraging its extensive R&D capabilities and global market access. A definitive agreement between the two companies is expected soon. Technically, is in a clear downtrend, trading below key moving averages on the daily chart. The stock is currently at ₹630.40, facing resistance near the 9-day EMA at ₹646.60 and the 70-day EMA at ₹740.62, both of which indicate bearish momentum. The 100-day EMA at ₹776.15 suggests a long-term downward bias. Strong resistance is visible at ₹691.70, while immediate support is at ₹590, followed by a major support zone at ₹557.80. The RSI at 40.91 is in a weak zone, indicating bearish sentiment but not yet in oversold territory, meaning further downside remains possible. The price action suggests that unless the stock reclaims the ₹690–700 zone, the trend remains negative, and a break below ₹590 could accelerate selling pressure. However, a reversal with volume above ₹650-675 may signal short-term recovery towards ₹740.